What is COPD and why is it important?
Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by persistent airflow limitation, which usually progresses and is associated with an enhanced chronic inflammatory response of the airways and lungs to harmful particles or gases. Smoking is the most common cause, but air pollution, occupational hazards, and genetic factors also contribute. COPD includes conditions such as chronic bronchitis (with its characteristic cough and sputum production) and pulmonary emphysema.
COPD symptoms, such as shortness of breath, chronic cough, and wheezing, significantly reduce patients' quality of life. COPD treatment is aimed at relieving symptoms, preventing exacerbations, and slowing the progression of the disease. However, in addition to primary treatment strategies, it is crucial to pay attention to complications that can significantly worsen the patient's condition.
Pulmonary hypertension: a serious complication of COPD
One of the significant and common complications of chronic obstructive pulmonary disease, especially in patients with severe forms of COPD, is pulmonary hypertension (PH) [1]. This is a condition in which pressure in the pulmonary arteries increases, which creates an additional burden on the right side of the heart and can lead to right ventricular failure.
A number of factors contribute to the development of pulmonary hypertension in COPD. In particular, pulmonary emphysema, which often accompanies COPD, leads to lung hyperinflation (an increase in lung volume), which can contribute to the development of PH [1]. Lung hyperinflation alters breathing mechanics and vascular resistance, which ultimately affects pressure in the pulmonary vessels.
It is important to note that patients with COPD can be classified into different PH groups due to frequent comorbidities, which complicates diagnosis and the choice of therapy [1].
Diagnosis and treatment approaches for pulmonary hypertension in COPD
Treating pulmonary hypertension in patients with COPD is a complex task, as the response to therapy can vary significantly depending on the patient's phenotype [1]. This means that individual characteristics of the disease and the presence of lung hyperinflation can affect the effectiveness of chosen treatment methods. Studies show that the degree of lung hyperinflation in COPD patients can be a predictor of response to PH treatment [1].
In general, approaches to treating pulmonary hypertension include:
- Drug therapy: Various groups of drugs are used, aimed at dilating pulmonary vessels and reducing pressure. However, their effectiveness in PH associated with COPD can be variable [1].
- Oxygen therapy: Supplemental oxygen helps reduce hypoxia, which is one of the triggers for pulmonary hypertension.
- Treatment of the underlying disease: Optimizing COPD therapy (bronchodilators, corticosteroids, rehabilitation) is the cornerstone of managing PH associated with COPD.
There are other forms of pulmonary hypertension, such as chronic thromboembolic pulmonary hypertension (CTEPH), which is a complication of pulmonary embolism. For CTEPH, the primary treatment method is pulmonary endarterectomy, but drug therapy and balloon pulmonary angioplasty are also used [4]. Although this is a separate condition, progress in treating various forms of PH can influence general approaches to therapy.
Prospects and new directions in therapy
The search for new, more effective methods for treating pulmonary hypertension continues. One such promising direction is the development of targeted drugs. For example, sotatercept is a new therapeutic agent targeting the activin receptor signaling pathway, which plays a role in the development of pulmonary arterial hypertension (PAH) [5]. This drug has received priority review status from the US Food and Drug Administration (FDA), which underscores the urgent need for new pharmacological interventions for this rare and severe condition. Although sotatercept is primarily intended for PAH, its success may open new paths for study and application in other forms of PH, including that associated with COPD.
An individualized approach to treatment, based on the patient's phenotype and the degree of lung hyperinflation, is key to improving outcomes in the treatment of pulmonary hypertension in COPD [1].
Living with COPD: a comprehensive approach
Managing COPD is a lifelong process that requires a comprehensive approach. In addition to specific treatment for complications such as pulmonary hypertension, patients need to:
- Quit smoking completely.
- Follow recommendations for drug therapy (bronchodilators, inhaled corticosteroids if necessary).
- Regularly undergo pulmonary rehabilitation.
- Get vaccinated against influenza and pneumococcal infection.
- Lead a healthy lifestyle, including a balanced diet and moderate physical activity.
- Visit a doctor regularly to monitor their condition and adjust treatment.
Timely diagnosis and adequate treatment of complications, such as pulmonary hypertension, play a decisive role in improving the prognosis and quality of life for patients with COPD.
Sources
- [1] Pulmonary hypertension in patients with chronic obstructive pulmonary disease: Impact of lung hyperinflation on the response to pulmonary hypertension treatment. https://pubmed.ncbi.nlm.nih.gov/39765128/
- [4] Chronic thromboembolic pulmonary hypertension treatment and sex: Systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/38908993/
- [5] Redefining Pulmonary Arterial Hypertension Treatment: Sotatercept's FDA Priority Review. https://pubmed.ncbi.nlm.nih.gov/39238729/
The information provided in this article is for reference purposes only and should not be used for self-diagnosis or self-treatment. Always consult a qualified medical professional for an accurate diagnosis and an individualized treatment plan.